Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.
-
XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).
-
Applied Biologics launches a preclinical OA program, expanding its biologic pipeline beyond chronic wounds into degenerative diseases.
-
Applied Biologics presents interim CAMPX Trial data at SAWC Spring 2026, highlighting encouraging wound closure trends for XWRAP® in diabetic foot ulcers.
-
Applied Biologics receives FDA IND clearance for BIOxHEAL, advancing its lead biologic therapy into Phase 3 clinical trials for diabetic foot ulcers.